In the current global emergency due to SARS-CoV-2 outbreak, passive immunotherapy emerges as a promising treatment for COVID-19. Among animal-derived products, equine formulations are still the cornerstone therapy for treating envenomations due to animal bites and stings. Therefore, drawing upon decades of experience in manufacturing snake antivenom, we developed and preclinically evaluated two anti-SARS-CoV-2 polyclonal equine formulations as potential alternative therapy for COVID-19. We immunized two groups of horses with either S1 (anti-S1) or a mixture of S1, N, and SEM mosaic (anti-Mix) viral recombinant proteins. Horses reached a maximum anti-viral antibody level at 7 weeks following priming, and showed no major adverse acute or chronic clinical alterations. Two whole-IgG formulations were prepared via hyperimmune plasma precipitation with caprylic acid and then formulated for parenteral use. Both preparations had similar physicochemical and microbiological quality and showed ELISA immunoreactivity towards S1 protein and the receptor binding domain (RBD). The anti-Mix formulation also presented immunoreactivity against N protein. Due to high anti-S1 and anti-RBD antibody content, final products exhibited high in vitro neutralizing capacity of SARS-CoV-2 infection, 80 times higher than a pool of human convalescent plasma. Pre-clinical quality profiles were similar among both products, but clinical efficacy and safety must be tested in clinical trials. The technological strategy we describe here can be adapted by other producers, particularly in low- and middle-income countries.
In the current global emergency due to SARS-CoV-2 outbreak, passive immuene">notherapy emerges as a promising treatmeene">nt for n class="Disease">COVID-19. Among animal-derived products, equine formulations are still the cornerstone therapy for treating envenomations due to animal bites and stings. Therefore, drawing upon decades of experience in manufacturing snake antivenom, we developed and preclinically evaluated two anti-SARS-CoV-2 polyclonal equine formulations as potential alternative therapy for COVID-19. We immunized two groups of horses with either S1 (anti-S1) or a mixture of S1, N, and SEM mosaic (anti-Mix) viral recombinant proteins. Horses reached a maximum anti-viral antibody level at 7 weeks following priming, and showed no major adverse acute or chronic clinical alterations. Two whole-IgG formulations were prepared via hyperimmune plasma precipitation with caprylic acid and then formulated for parenteral use. Both preparations had similar physicochemical and microbiological quality and showed ELISA immunoreactivity towards S1 protein and the receptor binding domain (RBD). The anti-Mix formulation also presented immunoreactivity against N protein. Due to high anti-S1 and anti-RBD antibody content, final products exhibited high in vitro neutralizing capacity of SARS-CoV-2 infection, 80 times higher than a pool of human convalescent plasma. Pre-clinical quality profiles were similar among both products, but clinical efficacy and safety must be tested in clinical trials. The technological strategy we describe here can be adapted by other producers, particularly in low- and middle-income countries.
Authors: Jordan R Barrett; Sandra Belij-Rammerstorfer; Christina Dold; Katie J Ewer; Pedro M Folegatti; Ciaran Gilbride; Rachel Halkerston; Jennifer Hill; Daniel Jenkin; Lisa Stockdale; Marije K Verheul; Catherine M Green; Adrian V S Hill; Teresa Lambe; Sarah Gilbert; Andrew J Pollard; Parvinder K Aley; Brian Angus; Duncan Bellamy; Eleanor Berrie; Sagida Bibi; Mustapha Bittaye; Miles W Carroll; Breeze Cavell; Elizabeth A Clutterbuck; Nick Edwards; Amy Flaxman; Michelle Fuskova; Andrew Gorringe; Bassam Hallis; Simon Kerridge; Alison M Lawrie; Aline Linder; Xinxue Liu; Meera Madhavan; Rebecca Makinson; Jack Mellors; Angela Minassian; Maria Moore; Yama Mujadidi; Emma Plested; Ian Poulton; Maheshi N Ramasamy; Hannah Robinson; Christine S Rollier; Rinn Song; Matthew D Snape; Richard Tarrant; Stephen Taylor; Kelly M Thomas; Merryn Voysey; Marion E E Watson; Daniel Wright; Alexander D Douglas Journal: Nat Med Date: 2020-12-17 Impact factor: 53.440
Authors: Jason Phua; Li Weng; Lowell Ling; Moritoki Egi; Chae-Man Lim; Jigeeshu Vasishtha Divatia; Babu Raja Shrestha; Yaseen M Arabi; Jensen Ng; Charles D Gomersall; Masaji Nishimura; Younsuck Koh; Bin Du Journal: Lancet Respir Med Date: 2020-04-06 Impact factor: 30.700
Authors: John Mair-Jenkins; Maria Saavedra-Campos; J Kenneth Baillie; Paul Cleary; Fu-Meng Khaw; Wei Shen Lim; Sophia Makki; Kevin D Rooney; Jonathan S Nguyen-Van-Tam; Charles R Beck Journal: J Infect Dis Date: 2014-07-16 Impact factor: 5.226
Authors: Alexandra C Walls; Young-Jun Park; M Alejandra Tortorici; Abigail Wall; Andrew T McGuire; David Veesler Journal: Cell Date: 2020-03-09 Impact factor: 41.582
Authors: William R Strohl; Zhiqiang Ku; Zhiqiang An; Stephen F Carroll; Bruce A Keyt; Lila M Strohl Journal: BioDrugs Date: 2022-04-27 Impact factor: 7.744
Authors: Myriam Belén González Viacava; Augusto Varese; Ignacio Mazzitelli; Laura Lanari; Lucía Ávila; María Julia García Vampa; Jorge Geffner; Osvaldo Cascone; José Christian Dokmetjian; Adolfo Rafael de Roodt; Matías Fingermann Journal: Antibodies (Basel) Date: 2022-01-02
Authors: Sonia Aparecida Andrade; João Victor Batalha-Carvalho; Rui Curi; Fan Hui Wen; Dimas Tadeu Covas; Ana Marisa Chudzinski-Tavassi; Ana Maria Moro Journal: Front Immunol Date: 2022-07-11 Impact factor: 8.786
Authors: Mustafa Buyukozkan; Sergio Alvarez-Mulett; Alexandra C Racanelli; Frank Schmidt; Richa Batra; Katherine L Hoffman; Hina Sarwath; Rudolf Engelke; Luis Gomez-Escobar; Will Simmons; Elisa Benedetti; Kelsey Chetnik; Guoan Zhang; Edward Schenck; Karsten Suhre; Justin J Choi; Zhen Zhao; Sabrina Racine-Brzostek; He S Yang; Mary E Choi; Augustine M K Choi; Soo Jung Cho; Jan Krumsiek Journal: iScience Date: 2022-06-17